Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Received: 22 February 2021
Accepted: 20 September 2021
First Online: 28 September 2021
: Written informed consent was obtained from all participants prior to inclusion in the study. The following table gives an overview on the Ethical committees that gave a positive opinion on the conduct of the HAEKA study.Name of Ethical Committee: Sign for HAEKA study; Ethikkommission an der Medizinischen Fakultät der Universität Rostock: A 2019-0046; Ethikkommission der Medizinischen Hochschule Hannover: 8825_BO_K_2019; Ethikkommission an der Medizinischen Fakultät der Universität Leipzig: 538/19-lk; Ethikkommission der Universität Ulm: 440/19; Ethikkommission des Fachbereichs Medizin der Goethe-Universität Frankfurt: 19-511; Ethikkommission der Landesärztekammer Rheinland-Pfalz: 2019-14773; Ethikkommission bei der Landesärztekammer Hessen: 2020-1512-zvBO; Ethikkommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität: 2020-469-b-S
: Not applicable.
: Toni M. Förster, Arndt Rolfs, and Volha Skrahina have been during the concept phase and initiation of the study CENTOGENE GmbH employees. Arndt Rolfs has been the founder of CENTOGENE GmbH and holds stock/stock options in the company. Selen Zülbahar and Susanne Zielke are CENTOGENE GmbH employees. Marcus Maurer reports personal fees from Alnylam, grants and personal fees from BioCryst, grants from CENTOGENE, grants and personal fees from CSL Behring, grants from Dyax, grants and personal fees from Kalvista, grants from Pharming, personal fees from Pharvaris, grants and personal fees from Shire/Takeda, outside the submitted work. Markus Magerl is a PI of a center of the HAEKA study. He further reports personal fees and non-financial support from Shire Takeda, personal fees and non-financial support from CSL Behring, personal fees from Pharming, personal fees and non-financial support from Biocryst, personal fees from Kalvista, personal fees from Octapharma, outside the submitted work. Donatello Crocetta is employee of Takeda. Neil Inhaber is employee of Takeda and holds stock/stock options in Takeda.